We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




World’s First Molecular, Cell-Based Test Offers Non-Surgical Method for Diagnosis and Staging of Endometriosis

By LabMedica International staff writers
Posted on 25 Jan 2023
Print article
Image: MetriDx is a diagnostic test for the definitive, early diagnosis and staging of endometriosis (Photo courtesy of Hera Biotech)
Image: MetriDx is a diagnostic test for the definitive, early diagnosis and staging of endometriosis (Photo courtesy of Hera Biotech)

Endometriosis is a very painful disorder in which tissue similar to that which normally lines the uterus migrates and grows on other organs outside of the uterus. The disease affects about 10-20% of women across the world and is responsible for a high majority of female infertility cases. Awareness of a patient’s endometriosis status and stage can save significant amounts of money spent on misdiagnosis and interventions that could be unsuitable for the stage of the disease. Additionally, during infertility, treatment of the underlying endometriosis before intervention can increase the chances of success by modifying the interventions after taking into account the underlying disease. Now, researchers will soon begin a clinical trial evaluating the world’s first molecular, cell-based test for diagnosing and staging endometriosis without surgery.

Hera Biotech (San Antonio, TX, USA) is developing and commercializing the world’s first non-surgical test for the definitive diagnosis and staging of endometriosis. Hera’s breakthrough approach is based on cutting edge, single cell, micro-fluidic analysis to identify endometriosis-specific biological markers. This approach enables clinicians to definitively diagnose endometriosis regardless of stage with unparalleled accuracy. A sample of the patient’s endometrium is collected using a uterine brush biopsy during an in-office procedure, thereby eliminating the need for surgery. MetriDx configuration utilizes micro-fluidic analysis of single cells obtained from the patient to definitively diagnose and stage endometriosis.

MetriDx can provide physicians with unprecedented diagnostic capability, reduce the liability risk for hospitals, eliminate unnecessary surgical procedures, and minimize the amount of time for patients before they receive a diagnosis, all the while maintaining tissue collection and a direct pathology diagnosis. MetriDx will initially be offered to both OB/GYN practices and those in the fertility solutions market as a laboratory developed test (LDT). MetriDx can also be utilized as a screening test in OB/GYN practices, in fertility clinics and by reproductive endocrinologist practices. The first patient for the proof-of-concept multi-center clinical trial of the MetriDx endometriosis diagnostic test has already been enrolled.

“Women in the US endure eight years and ten plus doctor’s visits, on average, before they get a diagnosis,” said CEO and Co-Founder Somer Baburek. “I want the process for obtaining a definitive answer about your endometriosis status to be as easy and as routine as getting a pap smear.”

Related Links:
Hera Biotech 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.